Skip to content
Screener

Fulgent Genetics, Inc. FLGT Q3 2025 earnings

Reported November 7, 2025 · Before market open

Revenue$84.1MMiss by $1.3M
EPS$0.14Beat by $0.38
Revenue estimate$85.4M
EPS estimate-$0.24

Next report

Nov 6, 2026 (in 2 months)
Revenue estimate$86.3M
EPS estimate-$0.65

Financials

Q3 2025

Income statement

See full
Revenue$84.1M+17.2%
Gross profit$35.5M+32.7%
Operating income-$15.4M+10.1%
Net income-$6.6M+54.9%
EPS (diluted)-$0.21+56.3%

Balance sheet

See full
Cash & equivalents$117.6M+103%
Total debt$5.6M-21.1%
Total equity$1.1B-1.1%
Total assets$1.2B-1.6%

Cash flow

See full
CapEx$6.1M-69.0%
Free cash flow-+100%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$691.76M+5.1%
Enterprise value$579.68M-4.6%
P/S2.2×-0.2×

Profitability

See full
Gross margin41.2%+5.0pp
Operating margin-22.5%-9.3pp
Net margin-13.6%-5.9pp

Returns & leverage

See full
Return on equity-3.8%-1.6pp
Debt / equity0×0.0×
Current ratio7×+2.6×

Segments

By segment

See full
Laboratory Services$83.9M+17.0%
Therapeutic Development$138.0K—

By geography

See full
Non Us$6.5M+7.0%
Other Countries$3.3M+2.4%

FAQ

When did Fulgent Genetics, Inc. report Q3 2025 earnings?
Fulgent Genetics, Inc. (FLGT) reported Q3 2025 earnings on November 7, 2025 before market open.
What were Fulgent Genetics, Inc.'s Q3 2025 revenue and EPS?
Fulgent Genetics, Inc. reported revenue of $84.1M and eps of $0.14 for Q3 2025.
Did Fulgent Genetics, Inc. beat estimates in Q3 2025?
Revenue missed the consensus estimate of $85.4M by $1.3M. EPS beat the consensus estimate of $-0.24 by $0.38.
How did Fulgent Genetics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 17.2% from $71.7M a year earlier and eps declined 54.8% from $0.31.
Where can I find Fulgent Genetics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-271006) and the 10-Q periodic report (0001193125-25-271013) directly on SEC EDGAR. The filing index links above go to sec.gov.